Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 30Carcinoma, Renal Cell 17Prostatic Neoplasms 13Carcinoma, Transitional Cell 11Melanoma 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Uterine Cervical Neoplasms 6Kidney Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Urothelial Cancer 2Testicular Neoplasms 2Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma in Situ 2Carcinoma 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × durvalumab × Genitourinary × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡